Scholarlink

Purpose <p>To compare the 6-month outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion (BRVOME).</p> Study design <p>Retrospective observational study.</p> Methods <p>The charts of consecutive treatment-naïve eyes with BRVOME treated with intravitreal injection therapy between December 2023 and August 2024 at Hikichi Eye Clinic (Sapporo, Japan) were reviewed; all eyes treated between December 2023 and April 2024 were administrated with aflibercept and all eyes treated between May 2024 and August 2024 were administrated with faricimab. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were assessed at baseline, 1, 3, and 6 months. Injection frequency and safety were also evaluated.</p> Results <p>Fifty-four eyes (29 aflibercept, 25 faricimab) were included. Both groups showed significant improvement in BCVA (from 0.39 ± 0.29 to 0.09 ± 0.23) and CFT (from 617 ± 132 to 201 ± 68 µm) over 6 months (<i>p</i> &lt; 0.001). The mean number of injections was significantly lower in the faricimab group (1.96 ± 0.68) than the aflibercept group (2.45 ± 0.87; <i>p</i> = 0.024). No serious adverse events were reported.</p> Conclusion <p>Faricimab achieved similar visual and anatomical outcomes to aflibercept while requiring fewer injections, suggesting a potential advantage in reducing treatment burden.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Six-month comparative outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion

  • 期刊论文

  • 发表日期：

    2025年7月22日

查看全文
  • Taiichi Hikichi,
  • Haruka Kurabe,
  • Amane Notoya,
  • Yuuna Oguro,
  • Misaki Hirano,
  • Yumeka Doi

摘要

Purpose

To compare the 6-month outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion (BRVOME).

Study design

Retrospective observational study.

Methods

The charts of consecutive treatment-naïve eyes with BRVOME treated with intravitreal injection therapy between December 2023 and August 2024 at Hikichi Eye Clinic (Sapporo, Japan) were reviewed; all eyes treated between December 2023 and April 2024 were administrated with aflibercept and all eyes treated between May 2024 and August 2024 were administrated with faricimab. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were assessed at baseline, 1, 3, and 6 months. Injection frequency and safety were also evaluated.

Results

Fifty-four eyes (29 aflibercept, 25 faricimab) were included. Both groups showed significant improvement in BCVA (from 0.39 ± 0.29 to 0.09 ± 0.23) and CFT (from 617 ± 132 to 201 ± 68 µm) over 6 months (p < 0.001). The mean number of injections was significantly lower in the faricimab group (1.96 ± 0.68) than the aflibercept group (2.45 ± 0.87; p = 0.024). No serious adverse events were reported.

Conclusion

Faricimab achieved similar visual and anatomical outcomes to aflibercept while requiring fewer injections, suggesting a potential advantage in reducing treatment burden.